Abstract
To date, the Her-2 receptor is the most frequently detected breast cancer biomarker which can be monitored on the surface of tumors by proton magnetic resonance imaging (1H MRI). In the past decade, we observed major advances in the development of 1H MRI as a diagnostic tool in cancer studies. 1H MRI is noninvasive method and can be used to explore tumor biology, cancer cell surface morphology and provide information about drug efficacy, absorption, distribution, and elimination. This review describes current studies of Her-2 targeting with trastuzumab and the application of 1H MRI to Her-2 receptor detection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
